lpath inc-class a (LPTN) Key Developments
Lpath Inc. - Special Call
Nov 16 15
To provide a corporate update and review data from the Nexus Phase 2 study that evaluated iSONEP as a treatment for patients with wet age-related macular degeneration
Lpath, Inc. to Present Nexus Phase 2 Study Data in Wet Age-Related Macular Degeneration At the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day
Nov 5 15
Lpath Inc. announced that data from the Nexus Phase 2 study of iSONEP will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day in Las Vegas, Nevada on November 14, 2015 at 12:59 p.m. Pacific Time. In May, Lpath announced that iSONEP did not meet the primary or key secondary endpoints in the Nexus trial, a prospective, randomized, Phase 2 clinical trial conducted in the U.S. that enrolled 158 patients with wet age-related macular degeneration (wet AMD) who had been subresponsive to treatment with existing anti-vascular endothelial growth factor (VEGF) therapies. Nexus trial patients did not show any statistically significant improvement in visual acuity at day 120 when treated with iSONEP as an adjunctive or monotherapy. Lpath conducted further analyses of the data including additional anatomical endpoints to better understand the results from each arm of the trial, and those findings will be included in the presentation at the AAO Annual Meeting.
Lpath Appoints Gary Atkinson Interim Chief Executive Officer
Sep 29 15
Lpath Inc. announced that Gary Atkinson has been appointed interim chief executive officer of Lpath, effective immediately. Mr. Atkinson will continue to serve as Lpath's chief financial officer. Mr. Atkinson joined Lpath as CFO in 2005, and has more than 20 years of experience with life science companies. Prior to Lpath, he served as the CFO for Quorex Pharmaceuticals, which was acquired by Pfizer. He also previously served as vice president of finance at Isis Pharmaceuticals, and as a financial consultant to Ichor Medical Systems. Earlier in his career, Mr. Atkinson served as the corporate controller at Loral Aerospace Corporation and as the director of financial planning at Cubic Corporation. Mr. Atkinson began his career at Ernst and Young. He is a graduate of Brigham Young University.
Lpath Inc. Initiates First-In-Human Dosing in Phase 1 Clinical Trial of Lpathomab
Sep 15 15
Lpath Inc. announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses. Lpathomab is an antibody targeting lysophosphatidic acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral adiculopathy. Other preclinical studies have also demonstrated the potential for Lpathomab as a treatment for traumatic brain injury.
Lpath Inc. Announces Plan to Begin Lpathomab Clinical Trial
Jul 23 15
Lpath Inc. announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.